Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Lufotrelvir

Small molecule · Inhibitor of SARS-CoV-2 3C-like protease (3CLpro) · developed by Pfizer

Phase 3 Most advanced trial (none active)
1 Registered trials

What is Lufotrelvir?

Lufotrelvir is a phosphate prodrug that is converted in the body to PF-00835231, an inhibitor of the coronavirus 3C-like protease. By blocking this enzyme, it prevents cleavage of viral polyproteins needed for viral replication. It is studied in COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PF-07304814
Drug type
Small molecule
Targets
SARS-CoV-2 3C-like protease (3CLpro)
Mechanism
Inhibitor of SARS-CoV-2 3C-like protease (3CLpro)
Pathways
viral polyprotein processing, viral RNA replication and transcription
Therapy area
Infectious disease
Developer
Pfizer
In trials of
VIR
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
XJ51YOB1SC

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04501978 Phase 3 Covid19 Completed VIR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Covid19

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.